UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1440-4
Program Prior Authorization/Notification
Medication Rivfloza™ (nedosiran)
P&T Approval Date 3/2024, 4/2024, 4/2025, 5/2025
Effective Date 8/1/2025
1. Background:
Rivfloza™ (nedosiran) is an LDHA-directed small interfering RNA indicated to lower urinary
oxalate levels in children 2 years of age and older and adults with primary hyperoxaluria type
1 (PH1) and relatively preserved kidney function (e.g., eGFR ≥ 30 mL/min/1.73 m2).
2. Coverage Criteriaa:
A. Initial Authorization
1. Rivfloza will be approved based on one of the following criteria:
a. All of the following:
(1) Patient has been established on therapy with Rivfloza under an active
UnitedHealthcare medical benefit prior authorization for the treatment of
primary hyperoxaluria type 1 (PH1)
-AND-
(2) Documentation of positive clinical response to Rivfloza
-AND-
(3) Patient is not receiving Rivfloza in combination with Oxlumo (lumasiran)
-OR-
b. All of the following:
(1) Diagnosis of primary hyperoxaluria type 1 (PH1)
-AND-
(2) Patient is at least 2 years of age and older
-AND-
(3) Patient has relatively preserved kidney function (e.g., eGFR ≥ 30 mL/min/1.73
m2)
-AND-
© 2025 UnitedHealthcare Services, Inc.
1
(4) Patient is not receiving Rivfloza in combination with Oxlumo (lumasiran)
Authorization will be issued for 12 months
B. Reauthorization
1. Rivfloza will be approved based on both of the following criteria:
a. Documentation of positive clinical response to Rivfloza therapy
-AND-
b. Patient is not receiving Rivfloza in combination with Oxlumo (lumasiran)
Authorization will be issued for 12 months
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-
authorization based solely on previous claim/medication history, diagnosis codes (ICD-
10) and/or claim logic. Use of automated approval and re-approval processes varies by
program and/or therapeutic class.
• Supply limits, Medical Necessity and/or Step Therapy may be in place.
4. References:
1. Rivfloza [package insert]. Plainsboro, NJ: Novo Nordisk, Inc.; March 2025.
Program Prior Authorization/Notification - Rivfloza (nedosiran)
Change Control
3/2024 New program.
4/2024 Removed footnote that program applies to PFS formulation only.
Specified “medical benefit” for prior UHC PA bypass.
4/2025 Annual review. No changes to coverage criteria.
5/2025 Updated age limitation based on update to FDA-labeled indication.
Updated reference.
© 2025 UnitedHealthcare Services, Inc.
2